Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Annals of Hematology|February 4, 2018
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studiesJean-Jacques Kiladjian, Paola Guglielmelli, Martin Griesshammer, et al.
Blood|December 19, 2013
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsHagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin BFritz Offner, Vladimir Krcmery, Marc Boogaerts, et al.
The New England Journal of Medicine|January 26, 2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseAndrew J Ullmann, Jeffrey H Lipton, David H Vesole, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Stem Cells (Dayton, Ohio)|June 4, 2009
Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantationDaniel L Worthley, Andrew Ruszkiewicz, Ruth Davies, et al.
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
The New England Journal of Medicine|January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
European Journal of Haematology|November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapyRuben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
Pageof 6